{"id":604632,"date":"2022-06-20T19:06:01","date_gmt":"2022-06-20T19:06:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=604632"},"modified":"2022-06-20T19:06:01","modified_gmt":"2022-06-20T19:06:01","slug":"atopic-dermatitis-market-is-predicted-to-grow-at-a-remarkable-cagr-by-2032-analyzes-delveinsight-key-companies-pfizer-abbvie-daiichi-sankyo-novartis-and-purgenesis","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/atopic-dermatitis-market-is-predicted-to-grow-at-a-remarkable-cagr-by-2032-analyzes-delveinsight-key-companies-pfizer-abbvie-daiichi-sankyo-novartis-and-purgenesis_604632.html","title":{"rendered":"Atopic Dermatitis Market is Predicted to Grow at a Remarkable CAGR by 2032, Analyzes DelveInsight | Key Companies – Pfizer, AbbVie, Daiichi Sankyo, Novartis, and PurGenesis"},"content":{"rendered":"
\n
\"Atopic<\/a><\/div>\n
\n
Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
DelveInsight’s “Atopic Dermatitis Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Atopic Dermatitis Market Size and Share in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).<\/div>\n

The Atopic Dermatitis market report<\/strong> covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2019 to 2032. It also evaluates the current treatment practice\/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. <\/p>\n

\"Atopic<\/p>\n

Atopic Dermatitis: An Overview<\/strong><\/p>\n

Atopic dermatitis (AD), also known as atopic eczema, is a type of inflammation of the skin (dermatitis). It results in itchy, red, swollen, and cracked skin. Clear fluid may come from the affected areas, which often thickens over time. While the condition may occur at any age, it typically starts in childhood with changing severity over the years. In children under one year of age much of the body may be affected. <\/p>\n

According to the National Eczema Association 2020, Itch is the most burdensome symptom of AD, followed by skin redness and dryness. A recent study of adults with moderate to severe AD found that 70.5% reported severe, unbearable itch in the past two weeks, 85.8% reported daily itch, and 62.8% reported itching at least 12 hours per day.<\/em><\/p>\n

Atopic Dermatitis Market Key Facts<\/strong><\/p>\n